ICT01 in combination with IL-2 in patients with advanced solid tumors
Ontology highlight
ABSTRACT:
DISEASE(S): Metastatic Colorectal Cancer,Pancreatic Adenocarcinoma Metastatic,Relapsed/refractory Patients With Advanced Solid Tumors : Metastatic Colorectal Cancer (crc) Or Metastatic Ovarian Cancer Or Metastatic Castration-resistant Prostate Cancer (mcrpc) Or Metastatic Pancreatic Ductal Adenocarcinoma (pdac),Castration-resistant Prostate Cancer,Ovarian Cancer Metastatic
PROVIDER: 2737005 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
Similar Datasets
Project description:BACKGROUND - IL-6 mediates graft-versus-host disease (GVHD) in experimental allogeneic stem cell transplantation (alloSCT) and is an attractive therapeutic target. METHODS - A registered phase I/II study (ACTRN12612000726853) of IL-6 receptor (IL-6R) neutralizing antibody administration on day -1 to patients receiving full or reduced-intensity conditioning (RIC) and alloSCT from HLA-matched sibling or unrelated donors with standard cyclosporin and methotrexate GVHD prophylaxis. The primary endpoint was incidence of grade II-IV acute GVHD. Outcomes were compared to a non-randomized but contemporaneous group of study patients receiving the same alloSCT in the absence of IL-6R mAb. FINDINGS - Cytokine and pharmacokinetic analysis confirmed transient IL-6 dysregulation in the first month after alloSCT with complete inhibition following IL-6R mAb administration. With median follow up of 497 days, the incidence of grade II-IV GVHD was 12.5% in recipients of IL-6R inhibition (n = 48) versus 41.5% in the (n = 53) control cohort (P = 0.001). Low rates of acute GVHD were noted in patients receiving IL-6R inhibition relative to control patients following both myeloablative (12.5% vs. 46.4%, P = 0.03) and RIC (12.5% vs. 36.0%, P = 0.04). The incidence of severe (grade III/IV) acute GVHD was 4.2% in recipients of IL-6R inhibition versus 20.8% in the control cohort (P = 0.012). Relapse and chronic GVHD were unchanged. Immune reconstitution was preserved in recipients of IL-6R inhibition, but qualitatively modified with suppression of known pathogenic STAT3-dependent pathways. INTERPRETATION - IL-6 is the principal detectable and dysregulated cytokine secreted after alloSCT and its inhibition is a potential new and simple strategy to protect from acute GVHD despite robust immune reconstitution and a sustained graft-versus-leukemia effect. Single colour, Illumina Human HT12v4 Beadarrays.
2014-09-09 | E-GEOD-61201 | biostudies-arrayexpress
Project description:BACKGROUND - IL-6 mediates graft-versus-host disease (GVHD) in experimental allogeneic stem cell transplantation (alloSCT) and is an attractive therapeutic target. METHODS - A registered phase I/II study (ACTRN12612000726853) of IL-6 receptor (IL-6R) neutralizing antibody administration on day -1 to patients receiving full or reduced-intensity conditioning (RIC) and alloSCT from HLA-matched sibling or unrelated donors with standard cyclosporin and methotrexate GVHD prophylaxis. The primary endpoint was incidence of grade II-IV acute GVHD. Outcomes were compared to a non-randomized but contemporaneous group of study patients receiving the same alloSCT in the absence of IL-6R mAb. FINDINGS - Cytokine and pharmacokinetic analysis confirmed transient IL-6 dysregulation in the first month after alloSCT with complete inhibition following IL-6R mAb administration. With median follow up of 497 days, the incidence of grade II-IV GVHD was 12.5% in recipients of IL-6R inhibition (n = 48) versus 41.5% in the (n = 53) control cohort (P = 0.001). Low rates of acute GVHD were noted in patients receiving IL-6R inhibition relative to control patients following both myeloablative (12.5% vs. 46.4%, P = 0.03) and RIC (12.5% vs. 36.0%, P = 0.04). The incidence of severe (grade III/IV) acute GVHD was 4.2% in recipients of IL-6R inhibition versus 20.8% in the control cohort (P = 0.012). Relapse and chronic GVHD were unchanged. Immune reconstitution was preserved in recipients of IL-6R inhibition, but qualitatively modified with suppression of known pathogenic STAT3-dependent pathways. INTERPRETATION - IL-6 is the principal detectable and dysregulated cytokine secreted after alloSCT and its inhibition is a potential new and simple strategy to protect from acute GVHD despite robust immune reconstitution and a sustained graft-versus-leukemia effect.
2014-09-09 | GSE61201 | GEO
Project description:Chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapies are effective in a subset of patients with solid tumors, but new approaches are needed to enhance efficacy and universally improve patient outcomes. IL-15 and IL-21 are common cytokine-receptor gamma chain family members with distinct, pleiotropic effects on T-cells and other lymphocytes. We found that self-delivery of these cytokines by CAR or TCR T-cells prevents functional exhaustion by repeated stimulation and limits the emergence of dysfunctional natural killer (NK)-like T-cells. Across different preclinical murine solid tumor models, we observe enhanced regression with each individual cytokine but the greatest anti-tumor efficacy when T-cells are armored with both. Thus, the co-expression of membrane-tethered IL-15 and IL-21 represents a technology to enhance the resilience and function of engineered T-cells against solid tumors and could be applicable to multiple therapy platforms and diseases.
2023-08-29 | GSE229651 | GEO
Project description:Tumor-associated macrophages (TAM) represent an abundant cell population of the immune infiltrate in solid tumors and have been shown to orchestrate escape from immune surveillance. Macrophages display a very plastic phenotype which is recapitulated in vitro by classifying certain subsets according to exposure with defined, individual cytokines. The tumor-promoting M2 macrophages are polarized in vitro by differentiating human monocyte-derived macrophages with the T helper cell type 2 (Th2) response cytokines interleukin-4 and interleukin-13 or the immunosuppressive cytokine interleukin-10. Notably, only the latter macrophage subset undergoes apoptosis when treated with the colony stimulating factor 1 receptor (CSF1R) blocking antibody emactuzumab. However, under physiologic conditions the phenotype of TAM is shaped by a combination of cytokines. Hence, we evaluated if the addition of IL-10 to IL-4 or IL-13 differentiated macrophages is able to override IL-4/-13 mediated signaling and to restore susceptibility to emactuzumab. Though addition of IL-10 did not restore emactuzumab susceptibility, we surprisingly detected that only IL-4 differentiated macrophages sustained their specific marker expression while IL-10 skewed the IL-13 differentiated macrophage profile towards the IL-10 regulated phenotype. In-depth characterization by gene expression profiling revealed unique signatures of IL-4+IL-10 and IL-13+IL-10 differentiated macrophage subsets characterized by upregulation of the canonical NFκB signaling or Wnt/β-catenin signaling pathways, respectively. In silico-based analysis of a large cohort of cancer patients revealed distinct interleukin-4 or interleukin-13 overexpression patterns in a subset of patients with partial co-expression of IL-10 but almost absent IL-4/IL-13 co-expression. These patients may have less TAM depletion under therapy with CSF1R inhibitors. Five different macrophage subtypes were differentiated for six days with respect to different cytokines and transcriptomically profiled with three biological replicates derived from three different human, healthy volunteer donors
2016-08-06 | E-GEOD-85260 | biostudies-arrayexpress
Project description:We conducted a randomized, double-blind, placebo-controlled trial in adults with moderate-to-severe AD unresponsive to conventional topical or systemic treatment. Fezakinumab (ILV-094; anti IL-22 monoclonal antibody) monotherapy was administered for 12 weeks (primary endpoint), and clinical responses were followed until week 20. AD transcriptome significantly improved at week 12 in fezakinumab vs. placebo (p<1E-18).
2018-09-17 | GSE99802 | GEO
Project description:Recombinant cytokines were the first modern immunotherapies to produce durable cures in metastatic cancer, but their application has been hampered by only modest efficacy and limited tolerability. Next-generation cytokine therapies are therefore under development to overcome the biological limitations of native cytokines. By analyzing single-cell transcriptomic data from tumor infiltrating lymphocytes (TIL), we found that components of the Interleukin-18 (IL-18) pathway are upregulated on activated and dysfunctional TIL, suggesting that IL-18 therapy could potentially restore anti-tumor immunity by stimulating these key effector cells. However, recombinant IL-18 therapy has consistently failed to demonstrate anti-tumor efficacy in clinical trials. Here we show that the secreted, high-affinity decoy receptor IL-18BP is frequently upregulated in the tumor microenvironment of diverse human cancers and syngeneic murine tumor models. Using directed evolution, we engineered a ‘decoy-resistant’ IL-18 (DR-18), which maintains signaling potential, but is impervious to binding and inhibition by IL-18BP. In contrast to wild-type IL-18, DR-18 exhibits potent anti-tumor efficacy as monotherapy and in combination with anti-PD-1 checkpoint immunotherapy in multiple tumor models. Mechanistically, DR-18 drives the development of poly-functional effector CD8+ T cells, decreases the prevalence of exhausted CD8+ T cells expressing the transcription factor TOX, and expands the pool of TCF1+ precursor CD8+ T cells. DR-18 also enhances NK cell activity and maturation to effectively treat anti-PD-1 resistant tumors that have lost MHC class I surface expression. Together, these results highlight the IL-18 pathway as a powerful target for immunotherapeutic intervention and implicate the secreted immune checkpoint IL-18BP as an obstacle to effective IL-18 immunotherapy.
2020-06-29 | GSE146609 | GEO
Project description:CAR-T cell therapy has demonstrated remarkable clinical efficacy, but challenges remain in the therapeutic application for solid tumors, primarily due to poor infiltration capacity, suboptimal activity, and tumor antigen escape. Here, we found that the chemokine CCL3 plays a significant role in modulating intratumoral T cell cytotoxicity. However, CCL3 alone is insufficient to sustain durable CAR-T cell mediated tumor killing, largely due to tumor-induced T cell death. In contrast, the combination of CCL3 with IL-7, a cytokine known to enhance T cell survival, exerted a potent synergistic effect. This combination significantly improved CAR-T cell infiltration and longevity in solid tumors, leading to robust anti-tumor efficacy without significant side effects or systemic toxicity. Mechanistically, CCL3 plus IL-7 promoted RUNX3 expression and facilitated the differentiation of CD69+CD103+ tissue-resident memory T (Trm) cells. Furthermore, treatment with CAR-T cells co-expressing CCL3 and IL-7 (3P7-CAR-T) remodeled the immune landscape of solid tumors, marked by an increased infiltration of M1-like macrophages and CD103+ migratory dendritic cells. These changes enhance antigen presentation, thereby promoting the priming of endogenous anti-tumor T cell responses. Taken together, our results demonstrate that CCL3 synergizes with IL-7 to augment CAR-T cell memory and therapeutic effectiveness in solid tumors.
2026-07-15 | GSE330502 | GEO
Project description:CAR-T cell therapy has demonstrated remarkable clinical efficacy, but challenges remain in the therapeutic application for solid tumors, primarily due to poor infiltration capacity, suboptimal activity, and tumor antigen escape. Here, we found that the chemokine CCL3 plays a significant role in modulating intratumoral T cell cytotoxicity. However, CCL3 alone is insufficient to sustain durable CAR-T cell mediated tumor killing, largely due to tumor-induced T cell death. In contrast, the combination of CCL3 with IL-7, a cytokine known to enhance T cell survival, exerted a potent synergistic effect. This combination significantly improved CAR-T cell infiltration and longevity in solid tumors, leading to robust anti-tumor efficacy without significant side effects or systemic toxicity. Mechanistically, CCL3 plus IL-7 promoted RUNX3 expression and facilitated the differentiation of CD69+CD103+ tissue-resident memory T (Trm) cells. Furthermore, treatment with CAR-T cells co-expressing CCL3 and IL-7 (3P7-CAR-T) remodeled the immune landscape of solid tumors, marked by an increased infiltration of M1-like macrophages and CD103+ migratory dendritic cells. These changes enhance antigen presentation, thereby promoting the priming of endogenous anti-tumor T cell responses. Taken together, our results demonstrate that CCL3 synergizes with IL-7 to augment CAR-T cell memory and therapeutic effectiveness in solid tumors.
2026-07-15 | GSE330826 | GEO
Project description:The aim of this study was to compare the signaling cascades initiated by the two closely related cytokines IL-2 and IL-15. Considering the relevance of protein tyrosine phosphorylation in signal transduction, in order to quantify changes in protein phosphorylation in response to IL-2 and IL-15, we combined triple SILAClabeling of leukemic T-cells with phosphotyrosine (pY)-specific antibody-based protein enrichment followed by mass spectrometry (MS) analysis. Following the strategy described above, we managed to decipher in detail the complex signaling networks triggered by IL-2 and IL-15. Interestingly, a large number of components of the three main signaling pathways known to be initiated in response to the interleukins (JAK/STAT; RAS/MAPK; PI3K/AKT) were identified.
2017-03-29 | MSV000080767 | MassIVE
Project description:Neoadjuvant immune checkpoint inhibitors (ICIs) improve event-free survival in metastatic melanoma, yet resistance and recurrence remain common. Here we evaluated pepinemab, a Semaphorin 4D (SEMA4D)–blocking antibody, in combination with anti-PD1 nivolumab and/or anti-CTLA4 ipilimumab in a pilot biomarker-driven neoadjuvant trial (NCT03769155) for patients with resectable metastatic melanoma. The primary endpoint was to determine if pepinemab combined with ICIs modulates phenotypic properties within the tumor microenvironment in a manner that enhances T effector cell infiltration. Secondary endpoints included safety and tolerability, pathological response rates and radiographical response. Patients received two neoadjuvant doses followed by curative-intent surgery and one year of adjuvant nivolumab. Pepinemab-containing regimens demonstrated manageable toxicity profiles and did not delay or preclude curative-intent surgical resection in the 38 patients treated. The trial met its primary endpoint, as enrichment of transcripts associated with activated dendritic cells and immune recruitment pathways was observed in tumors from patients receiving pepinemab-containing regimens. Further, immune remodeling was evident by formation of mature lymphoid aggregates resembling tertiary lymphoid structures that contained clonally expanded T cell receptor repertoires. Together, these findings support further evaluation of SEMA4D blockade as a strategy to modulate the tumor microenvironment and potentially augment immunotherapy in melanoma and other solid malignancies.
2026-09-17 | GSE347762 | GEO